Recursion Pharmaceuticals (RXRX) Capital Expenditures Growth (1y) (2021 - 2026)
Recursion Pharmaceuticals (RXRX) Capital Expenditures Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 38.18% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -27.93% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 227.76% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 0.57% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Recursion Pharmaceuticals | 1.59 Bn | 933.22 Mn | -6.02 Mn | -85.92% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -85.92% |
| Dec 31, 2025 | -502.54% |
| Sep 30, 2025 | -58.12% |
| Jun 30, 2025 | 74.30% |
| Mar 31, 2025 | -72.46% |
| Dec 31, 2024 | -89.14% |
| Sep 30, 2024 | 197,566.67% |
| Jun 30, 2024 | -18.09% |
| Mar 31, 2024 | 28.56% |
| Dec 31, 2023 | 577.82% |
| Sep 30, 2023 | 99.44% |
| Jun 30, 2023 | -2,976.79% |
| Mar 31, 2023 | 19.18% |
| Dec 31, 2022 | -156.05% |
| Sep 30, 2022 | -111.14% |
| Jun 30, 2022 | -100.67% |
| Mar 31, 2022 | 515.89% |
| Dec 31, 2021 | 21.07% |
| Sep 30, 2021 | 1,075.06% |
| Jun 30, 2021 | 1,790.97% |